Previous 10 | Next 10 |
2023-08-21 08:10:52 ET Summary PTC Therapeutics, Inc. lacks solid margins and revenue streams, increasing investment risks. The company focuses on developing medicines for rare disorders, but a failed drug test caused stock price to tumble. The company's profitability is low, ...
2023-08-04 00:05:23 ET PTC Therapeutics, Inc. (PTCT) Q2 2023 Earnings Conference Call August 03, 2023 04:30 PM ET Company Participants Ron Aldridge - Senior Director, Investor Relations Matthew Klein - Chief Executive Officer Eric Pauwels - Chief Business Officer...
2023-08-03 16:16:14 ET PTC Therapeutics press release ( NASDAQ: PTCT ): Q2 GAAP EPS of -$2.66 misses by $1.04 . Revenue of $213.8M (+28.8% Y/Y) beats by $7.86M . Cash, cash equivalents, and marketable securities was $337.9 million on June 30, 2023, compared to ...
PTC Therapeutics Provides Corporate Update and Reports Second Quarter Financial Results PR Newswire – Second-quarter 2023 total revenue of $214 million , representing 29% year-over-year growth – – Positive APHENITY and PIVOT-HD data readouts in...
2023-07-28 13:22:08 ET Larimar Therapeutics ( NASDAQ: LRMR ), which has a candidate in phase 2 for Friedreich's Ataxia ("FA"), is up 22% in Friday afternoon trading, a beneficiary of Biogen's ( BIIB ) announcement to acquire Reata Pharmaceuticals ( RETA ) for more th...
2023-07-21 14:53:45 ET PTC Therapeutics ( NASDAQ: PTCT ) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency, recommended extending the marketing authorization for its Roche ( OTCQX:RHHBY )-partnered treatment Evrysdi to include infants ...
CHMP Recommends Evrysdi® for Babies Under Two Months Old with Spinal Muscular Atrophy PR Newswire - Following ratification by the European Commission, Evrysdi will be available to treat all spinal muscular atrophy patients, including babies from birth - SOUTH PL...
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2023 Financial Results PR Newswire SOUTH PLAINFIELD, N.J. , July 20, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call...
PTC Therapeutics Co-Founder Allan Jacobson, Ph.D., Awarded 2023 Gruber Genetics Prize PR Newswire -- Dr. Jacobson recognized for his pioneering work in nonsense-mediated mRNA decay -- SOUTH PLAINFIELD, N.J. , July 19, 2023 /PRNewswire/ -- PTC Therape...
2023-07-17 17:09:58 ET PTC Therapeutics ( NASDAQ: PTCT ) said on Monday that it had appointed Pierre Gravier as chief financial officer. Gravier previously served as a managing director in the healthcare group of Perella Weinberg Partner. Press Release For f...
News, Short Squeeze, Breakout and More Instantly...
PTC Therapeutics Inc. Company Name:
PTCT Stock Symbol:
NASDAQ Market:
PTC Therapeutics Inc. Website:
PTC Therapeutics Announces Sepiapterin NDA Submission to FDA PR Newswire WARREN, N.J. , July 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin NDA to the U.S. FDA. The NDA submission is for the t...
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results PR Newswire WARREN, N.J. , July 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to r...
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $32.00 for PTCT on 2024-07-12 08:15:00. The adjusted price target was set to $32.00. At the time of the announcement, PTCT was trading at $33.2. The overall price target consensus is at $43....